Wikidata

(Q106975759)

English

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (2021-06-30)

clinical trial

In more languages
default values for all languages
No label defined

No description defined

Statements

title
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (English)
0 references
country
Austria
0 references
Belgium
0 references
Finland
0 references
France
0 references
Germany
0 references
Hungary
0 references
Israel
0 references
Italy
0 references
Japan
0 references
Norway
0 references
Poland
0 references
Romania
0 references
Spain
0 references
Republic of China
0 references
Turkey
0 references
United Kingdom
0 references
start time
30 June 2021
0 references
end time
28 November 2023
0 references
number of participants
212
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q106975759&oldid=2148636119"